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resistance to the multi-drug resistance mechanisms which 
have already been described in other Gram-positive 
bacteria.
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Sir,
In 1993, we described a prolonged outbreak of infections 
caused by Acinetobacter baumanii in the intensive care 
units (ICUs) of a tertiary care hospital.1 Two strains of A . 
baumanii that had a comnxon protein profile but were dis­
tinguishable by carbon source growth requirements, were 
causally implicated during successive 12- and 8-month
periods of the outbreak. The shift in carbon source 
growth pattern appeared to coincide with the conversion 
of the strains from susceptible to ciprofloxacin to resist­
ant. Apart from the two epidemic strains, several sporadic 
isolates of Acinetobacter spp., all susceptible to the 
quinolones, were recovered throughout the period of the 
outbreak. The present study was undertaken to identify 
the isolates according to recent taxonomic criteria, to type 
them and to determine their susceptibilities to six anti­
microbial agents.
Fifty-two strains of Acinetobacter spp. were isolated 
from 43 adult patients on the ICUs of a single hospital 
over a 20-month period (January 1984-October 1985). 
The sources of the isolates were as follows: blood (one 
strain); cerebrospinal fluid (one); bronchial secretions 
(36); urine (seven); and other specimens (seven). Identifi­
cation to genomic species level according to recent 
taxonomic criteria2 was performed by DNA-DNA 
hybridization3 and the strains were typed by analysis of 
cell envelope protein with SDS-PAGE and assimilation 
of carbon sources.1 MICs were determined by an agar 
dilution method. The antibiotics tested included pipera­
cillin, ceftazidime, tobramycin, amikacin, norfloxacin 
and ciprofloxacin. The medium used was DST agar 
(Oxoid, Basingstoke, UK) and the inoculum 104 cfu/spot. 
Escherichia coli ATCC 25922 and Pseudom onas aerugi­
nosa ATCC 27853 were included as controls. After incu­
bation for 24 h at 35°C, the MIC was defined as the lowest 
concentration of each antibiotic that inhibited visible 
growth. Antimicrobial drug use was expressed in terms of 
defined daily doses (DDD), as recommended by the 
WHO Drug Utilization Research Group.4
Typing allowed the isolates to be assigned to three 
groups (A, B and C). Group A comprised 27 strains with 
common protein and assimilation profiles; all of these 
strains were identified by DNA-DNA hybridization as 
A. baumanii. Group B comprised 13 isolates, also identi­
fied as A . baum anii, which differed from those in group A 
only in terms of their carbon source profiles. The remain­
ing 12 isolates (group C) were characterized by a wide 
range of protein profiles, none of which were common to 
group A or B strains, and carbon source profiles that also 
differed from those of groups A  and B. One of these 12 
strains was identified as Acinetobacter calcoaceticus 
(DNA group 1), five as A . baumanii (DNA group 2) and 
six as the unnamed DNA group 3.
The MICs of the six antibiotics tested for the three 
groups are shown in the Table. With the exception of the 
quinolones, norfloxacin and ciprofloxacin, the MICs for 
strains belonging to groups A and B were similar. The 
MICs of ciprofloxacin for group A strains, which were 
isolated during the first 12 months of the 20-month out­
break, ranged from 0.25 to 2 mg/L. In contrast, the MICs 
of ciprofloxacin for strains belonging to group B, all but 
one of which were isolated during months 14-19 of the 
outbreak, ranged from 4 to 8 mg/L. This striking increase
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Table. MICs (mg/L) for Acinetobacter spp. classified into three 
groups according to protein profiling and carbon source growth
Range of MICs (median)
Group A Group B Group C
Antibiotic (n = 27) (n = 13) (n = 12)
Piperacillin >256 >256 2-32 (16)
Ceftazidime 4-16 (8) 8-16 (8) 1-8 (8)
Tobramycin 0.5-2 (1) 0.5-4 (2) <0.12-0.5 (0.25)
Amikacin 1-8 (4) 1-16 (4) 0.5-4 (1)
Norfloxacin 4-16 (8) 32-128 (64) 2-32 (8)
Ciprofloxacin 0.25-2 (1) 4-8(8) <0.12-2 (0.5)
in resistance appeared to coincide with the introduction 
of ciprofloxacin on to the ICUs during the eighth month 
of the study period. Data from the hospital pharmacy 
revealed that a total of 260 g of ciprofloxacin (277 DDD) 
were prescribed in 1984. This increased to 2130 g (1224 
DDD) during the first 8 months of 1985. With one 
exception, all of the isolates belonging to group C, which 
were recovered throughout the 20 months of the out­
break, were susceptible to all of the antimicrobials tested, 
including the quinolones.
The two successive outbreak strains had a common 
protein profile, but were distinguishable on the basis of 
carbon source growth profile and antibiotic susceptibility 
pattern. In a recent study, Dijkshoorn et ciL5 demonstrated 
that 12 of 14 outbreaks in various European countries 
were caused by two clones of A. baumanii (I and II). 
Isolates belonging to each clone were indistinguishable 
or, at least, very similar in terms of genomic fingerprint 
and protein profiles. The various outbreak strains were 
characterized by different biotypes and antibiograms, but 
all were highly resistant to most antibiotics. Apparently, 
strains belonging to these clones represent biological 
entities that are capable of colonizing patients and acquir­
ing genes encoding resistance to multiple antibiotics. The 
protein patterns of the A. baumanii strains of both groups 
A and B in the present study were indistinguishable. 
Moreover, the patterns closely resembled that of the 
clone I strains associated with the outbreaks described 
above.1,5 We cannot be sure if the emergence of 
ciprofloxacin resistance in group B strains was the result 
of the development of resistance in group A strains or of 
the introduction of a new strain of the clone I type into
the hospital. Regardless, the data suggest that selective 
pressures exerted by ciprofloxacin were accompanied by 
the rapid emergence of epidemic A. baumanii strains 
resistant to quinolones. Although Acinetobacter spp. 
are not normally particularly virulent, their potential to 
colonize and infect immunocompromised and other 
severely ill patients, combined with the potential to 
acquire genes conferring resistance to multiple antibiotics, 
is a major cause of concern. We therefore recommend 
extreme caution in the use of quinolones in hospitals 
where Acinetobacter spp. are endemic.
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